BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Axitinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Axitinib\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05768464-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Axitinib: Phase 2 readout est. (NCT05768464)
DESCRIPTION:Axitinib\, phase 2\, Renal Cell Carcinoma.\nStudy: Postoperativ
 e Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recur
 rence Factors\nEstimated primary completion: 30 December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/axitinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05768464
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03297606-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Axitinib: Phase 2 readout est. (NCT03297606)
DESCRIPTION:Axitinib\, phase 2.\nStudy: Canadian Profiling and Targeted Age
 nt Utilization Trial (CAPTUR)\nEstimated primary completion: 31 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/axitinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT03297606
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05059522-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Axitinib: Phase 3 readout est. (NCT05059522)
DESCRIPTION:Axitinib\, phase 3.\nStudy: Continued Access Study for Particip
 ants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are
  Closing\nEstimated primary completion: 31 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/axitinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05059522
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03839498-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Axitinib: Phase 2 readout est. (NCT03839498)
DESCRIPTION:Axitinib\, phase 2.\nStudy: Study of Axitinib (AG-013736) With 
 Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma\nEstimate
 d primary completion: January 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/axitinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT03839498
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07159191-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:Axitinib: Phase 2 readout est. (NCT07159191)
DESCRIPTION:Axitinib\, phase 2\, Renal Cell Carcinoma.\nStudy: Envafolimab 
 Combined With Axitinib as First-Line Treatment for Patients With Advanced 
 Renal Cell Carcinoma\nEstimated primary completion: 20 February 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/axitinib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07159191
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06889649-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Axitinib: Phase 2 readout est. (NCT06889649)
DESCRIPTION:Axitinib\, phase 2.\nStudy: SABR Combined with Axitinib and Tor
 ipalimab in Recurrent or Metastatic RCC\nEstimated primary completion: 28 
 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/axitin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6889649
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06962787-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Axitinib: Phase 2 readout est. (NCT06962787)
DESCRIPTION:Axitinib\, phase 2.\nStudy: A Study of BL-B01D1+TKI±Pembrolizu
 mab in Patients With Locally Advanced or Metastatic Renal Cancer\nEstimate
 d primary completion: May 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/axitinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06962787
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05384496-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Axitinib: Phase 2 readout est. (NCT05384496)
DESCRIPTION:Axitinib\, phase 2.\nStudy: Axitinib and Nivolumab for the Trea
 tment of Mucosal Melanoma\nEstimated primary completion: May 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/axitinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05384496
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Axitinib: Phase 2 readout est. (NCT02925234)
DESCRIPTION:Axitinib\, phase 2.\nStudy: The Drug Rediscovery Protocol (DRUP
  Trial)\nEstimated primary completion: September 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/axitinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07123090-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Axitinib: Phase 2 readout est. (NCT07123090)
DESCRIPTION:Axitinib\, phase 2\, Renal Cell Carcinoma.\nStudy: A Study of S
 asanlimab\, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma\nE
 stimated primary completion: 1 October 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/axitinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07123090
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227415-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20271102
DTEND;VALUE=DATE:20271103
SUMMARY:Axitinib: Phase 1/2 readout est. (NCT07227415)
DESCRIPTION:Axitinib\, phase 1/2\, Renal Cell Carcinoma.\nStudy: Symbiotic-
 GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone 
 and in Combination With Other Anticancer Therapies in Adults With Locally 
 Advanced or Metastatic Renal Cell Cancer\nEstimated primary completion: 2 
 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/axitin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7227415
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07744932-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Axitinib: Phase 2 readout est. (NCT07744932)
DESCRIPTION:Axitinib\, phase 2\, Renal Cell Carcinoma.\nStudy: SABR Combine
 d With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma\n
 Estimated primary completion: 30 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/axitinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07744932
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816770-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Axitinib: Phase 2 readout est. (NCT07816770)
DESCRIPTION:Axitinib\, phase 2\, Renal Cell Carcinoma.\nStudy: MANTIS-RCC: 
 Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and
  Renal Medullary Carcinomas\nEstimated primary completion: 30 December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/axitinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07816770
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06424626-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Axitinib: Phase 1 readout est. (NCT06424626)
DESCRIPTION:Axitinib\, phase 1.\nStudy: A Trial of AK104 or AK112 in Combin
 ation With Axitinib in Patients With Metastatic Mucosal Melanoma\nEstimate
 d primary completion: 31 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/axitinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06424626
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04693468-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Axitinib: Phase 1 readout est. (NCT04693468)
DESCRIPTION:Axitinib\, phase 1.\nStudy: Talazoparib and Palbociclib\, Axiti
 nib\, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumo
 rs\, TalaCom Trial\nEstimated primary completion: 31 December 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/axitinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT04693468
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07776717-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Axitinib: Phase 2 readout est. (NCT07776717)
DESCRIPTION:Axitinib\, phase 2\, Renal Cell Carcinoma.\nStudy: TACTIC-RCC: 
 Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive 
 Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell Carcinoma\nEsti
 mated primary completion: 31 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/axitinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07776717
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05738694-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Axitinib: Phase 3 readout est. (NCT05738694)
DESCRIPTION:Axitinib\, phase 3\, Renal Cell Carcinoma.\nStudy: Neoadjuvant 
 of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Re
 nal Cell Carcinoma\nEstimated primary completion: 31 December 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/axitinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05738694
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07630363-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Axitinib: Phase 1/2 readout est. (NCT07630363)
DESCRIPTION:Axitinib\, phase 1/2\, Renal Cell Carcinoma.\nStudy: PTC-Guided
  Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC\nEstimated pri
 mary completion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/axitinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07630363
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07500831-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Axitinib: Phase na readout est. (NCT07500831)
DESCRIPTION:Axitinib\, phase na\, Renal Cell Carcinoma.\nStudy: Fasting-Mim
 icking Diet Combined With IO-TKI Combination Therapy in Patients With Meta
 static Renal Cell Carcinoma\nEstimated primary completion: April 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/axitinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07500831
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05536141-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Axitinib: Phase 1 readout est. (NCT05536141)
DESCRIPTION:Axitinib\, phase 1\, Renal Cell Carcinoma.\nStudy: A Phase 1 St
 udy of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma
  and Other Solid Tumors\nEstimated primary completion: March 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/axitinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05536141
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04341181-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Axitinib: Phase 2 readout est. (NCT04341181)
DESCRIPTION:Axitinib\, phase 2.\nStudy: ProTarget - A Danish Nationwide Cli
 nical Trial on Targeted Cancer Treatment Based on Genomic Profiling\nEstim
 ated primary completion: 30 April 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/axitinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04341181
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07469683-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Axitinib: Phase 2 readout est. (NCT07469683)
DESCRIPTION:Axitinib\, phase 2\, Renal Cell Carcinoma.\nStudy: An Open-labe
 l\, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety 
 of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib M
 onotherapy as a Second-line Treatment for Locally Advanced or Metastatic C
 lear Cell Renal Cell Carcinoma\nEstimated primary completion: October 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/axitinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07469683
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07277972-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Axitinib: Phase 2 readout est. (NCT07277972)
DESCRIPTION:Axitinib\, phase 2\, Renal Cell Carcinoma.\nStudy: Iparomlimab 
 and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for 
 the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carc
 inoma That Has Failed First-Line Systemic Therapy\nEstimated primary compl
 etion: 30 November 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/axitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07277972
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06485908-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20320229
DTEND;VALUE=DATE:20320301
SUMMARY:Axitinib: Phase 1/2 readout est. (NCT06485908)
DESCRIPTION:Axitinib\, phase 1/2.\nStudy: Axitinib and Oral Metronomic Etop
 oside for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma 
 and Ependymoma\nEstimated primary completion: February 2032. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/axitinib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06485908
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06364631-2214@assetmemo.bio
DTSTAMP:20261121T004052Z
DTSTART;VALUE=DATE:20320505
DTEND;VALUE=DATE:20320506
SUMMARY:Axitinib: Phase 3 readout est. (NCT06364631)
DESCRIPTION:Axitinib\, phase 3.\nStudy: CARE1 Pragmatic Clinical Trial\nEst
 imated primary completion: 5 May 2032. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/axitinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06364631
URL:https://assetmemo.bio/drug/axitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
